TXG 10x Genomics | $90.36 +0.4% | 9/29/2026 | | Boost Price Target | $40.00 ➝ $90.00 | Market Perform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 9/29/2026 |
TWST Twist Bioscience | $193.24 +3.8% | 9/29/2026 | | Boost Price Target | $160.00 ➝ $190.00 | Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/29/2026 |
ILMN Illumina | $273.68 +0.6% | 9/29/2026 | | Boost Price Target | $220.00 ➝ $300.00 | Outperform | 00.00% | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 9/29/2026 |
BRKR Bruker | $64.75 +0.4% | 9/29/2026 | | Boost Price Target | $60.00 ➝ $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 9/29/2026 |
ACHC Acadia Healthcare | $27.50 -1.9% | 9/23/2026 | | Boost Price Target | $30.00 ➝ $33.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Acadia Healthcare (NASDAQ:ACHC) on 9/23/2026 |
ANAB AnaptysBio | $50.26 -0.2% | 9/23/2026 | | Lower Price Target | $90.00 ➝ $81.00 | Outperform | 00.00% | View details for Leerink Partners rating of AnaptysBio (NASDAQ:ANAB) on 9/23/2026 |
CLDX Celldex Therapeutics | $32.49 +2.7% | 9/23/2026 | | Boost Price Target | $70.00 ➝ $88.00 | Outperform | 00.00% | View details for Leerink Partners rating of Celldex Therapeutics (NASDAQ:CLDX) on 9/23/2026 |
LXEO Lexeo Therapeutics | $3.38 -1.2% | 9/23/2026 | | Reiterated Rating | $15.00 | Outperform | 00.00% | View details for Leerink Partners rating of Lexeo Therapeutics (NASDAQ:LXEO) on 9/23/2026 |
OBX Obsidian Therapeutics | $13.73 -5.8% | 9/22/2026 | | Initiated Coverage | $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of Obsidian Therapeutics (NASDAQ:OBX) on 9/22/2026 |
BLSM BlossomHill Therapeutics | $18.66 -12.7% | 9/21/2026 | | Boost Price Target | $36.00 ➝ $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/21/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
|
VRTX Vertex Pharmaceuticals | $522.81 -0.7% | 9/21/2026 | | Initiated Coverage | $594.00 | Outperform | 00.00% | View details for Leerink Partners rating of Vertex Pharmaceuticals (NASDAQ:VRTX) on 9/21/2026 |
ELOX Eloxx Pharmaceuticals | $15.31 -0.7% | 9/18/2026 | | Set Price Target | $32.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026 |
ARDT Ardent Health | $10.35 -2.2% | 9/18/2026 | | Reiterated Rating | $14.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ardent Health (NYSE:ARDT) on 9/18/2026 |
ELOX Eloxx Pharmaceuticals | $15.31 -0.7% | 9/18/2026 | | Upgrade | $32.00 | Strong-Buy | 00.00% | View details for Leerink Partners rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 9/18/2026 |
ENTX Entera Bio | $2.91 +8.2% | 9/18/2026 | | Initiated Coverage | $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of Entera Bio (NASDAQ:ENTX) on 9/18/2026 |
HCA HCA Healthcare | $427.31 -1.0% | 9/18/2026 | | Reiterated Rating | $492.00 | Outperform | 00.00% | View details for Leerink Partners rating of HCA Healthcare (NYSE:HCA) on 9/18/2026 |
THC Tenet Healthcare | $256.07 -0.6% | 9/18/2026 | | Reiterated Rating | $309.00 | Outperform | 00.00% | View details for Leerink Partners rating of Tenet Healthcare (NYSE:THC) on 9/18/2026 |
UHS Universal Health Services | $174.49 -0.7% | 9/18/2026 | | Boost Price Target | $198.00 ➝ $205.00 | Outperform | 00.00% | View details for Leerink Partners rating of Universal Health Services (NYSE:UHS) on 9/18/2026 |
TWST Twist Bioscience | $193.24 +3.8% | 9/17/2026 | | Boost Price Target | $120.00 ➝ $160.00 | Outperform | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 9/17/2026 |
BBNX Beta Bionics | $18.98 -2.2% | 9/14/2026 | | Boost Price Target | $24.00 ➝ $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of Beta Bionics (NASDAQ:BBNX) on 9/14/2026 |
LRMR Larimar Therapeutics | $3.19 +1.6% | 9/14/2026 | | Initiated Coverage | $13.00 | Outperform | 00.00% | View details for Leerink Partners rating of Larimar Therapeutics (NASDAQ:LRMR) on 9/14/2026 |
PTCT PTC Therapeutics | $64.78 -0.3% | 9/14/2026 | | Initiated Coverage | $98.00 | Hold ➝ Outperform | 00.00% | View details for Leerink Partners rating of PTC Therapeutics (NASDAQ:PTCT) on 9/14/2026 |
RYTM Rhythm Pharmaceuticals | $95.21 -0.5% | 9/14/2026 | | Initiated Coverage | $133.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rhythm Pharmaceuticals (NASDAQ:RYTM) on 9/14/2026 |
XERS Xeris Biopharma | $9.56 -4.2% | 9/10/2026 | | Boost Price Target | $12.00 ➝ $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of Xeris Biopharma (NASDAQ:XERS) on 9/10/2026 |
BBOT BridgeBio Oncology Therapeutics | $4.10 +4.6% | 9/10/2026 | | Lower Price Target | $27.00 | Outperform | 00.00% | View details for Leerink Partners rating of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) on 9/10/2026 |
PHVS Pharvaris | $31.72 0.0% | 9/9/2026 | | Boost Price Target | $50.00 ➝ $65.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pharvaris (NASDAQ:PHVS) on 9/9/2026 |
EVMN Evommune | $8.22 -1.5% | 9/9/2026 | | Lower Price Target | $28.00 ➝ $22.00 | Outperform | 00.00% | View details for Leerink Partners rating of Evommune (NYSE:EVMN) on 9/9/2026 |
BLCO Bausch + Lomb | $17.03 -0.6% | 9/9/2026 | | Initiated Coverage | $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026 |
COLL Collegium Pharmaceutical | $21.82 -1.8% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026 |
AMRX Amneal Pharmaceuticals | $20.14 -0.3% | 9/9/2026 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026 |
PHAT Phathom Pharmaceuticals | $7.30 -0.8% | 9/9/2026 | | Initiated Coverage | $10.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026 |
HROW Harrow | $30.80 -1.9% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026 |
VTRS Viatris | $17.72 -2.2% | 9/9/2026 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026 |
AMRX Amneal Pharmaceuticals | $20.14 -0.3% | 9/9/2026 | | Initiated Coverage | $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Amneal Pharmaceuticals (NASDAQ:AMRX) on 9/9/2026 |
ANIP ANI Pharmaceuticals | $72.72 +0.1% | 9/9/2026 | | Initiated Coverage | $104.00 | Outperform | 00.00% | View details for Leerink Partners rating of ANI Pharmaceuticals (NASDAQ:ANIP) on 9/9/2026 |
BLCO Bausch + Lomb | $17.03 -0.6% | 9/9/2026 | | Initiated Coverage | $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bausch + Lomb (NYSE:BLCO) on 9/9/2026 |
COLL Collegium Pharmaceutical | $21.82 -1.8% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Collegium Pharmaceutical (NASDAQ:COLL) on 9/9/2026 |
HROW Harrow | $30.80 -1.9% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Harrow (NASDAQ:HROW) on 9/9/2026 |
MRK Merck & Co., Inc. | $145.74 -2.4% | 9/9/2026 | | Boost Price Target | $127.00 ➝ $161.00 | Outperform | 00.00% | View details for Leerink Partners rating of Merck & Co., Inc. (NYSE:MRK) on 9/9/2026 |
NAUT Nautilus Biotechnology | $1.42 +4.0% | 9/9/2026 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Leerink Partners rating of Nautilus Biotechnology (NASDAQ:NAUT) on 9/9/2026 |
MILLIONAIRE MASTERCLASS INVITE: Altucher (Ad) James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th.
Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans.
Attendees who join early can also access a $1,000 bonus offer included with the presentation. Watch James Altucher's free masterclass before December 8th |
PCRX Pacira BioSciences | $25.05 -2.3% | 9/9/2026 | | Initiated Coverage | $28.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Pacira BioSciences (NASDAQ:PCRX) on 9/9/2026 |
PHAT Phathom Pharmaceuticals | $7.30 -0.8% | 9/9/2026 | | Initiated Coverage | $10.00 | Hold | 00.00% | View details for Leerink Partners rating of Phathom Pharmaceuticals (NASDAQ:PHAT) on 9/9/2026 |
TEVA Teva Pharmaceutical Industries | $39.64 -0.4% | 9/9/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Leerink Partners rating of Teva Pharmaceutical Industries (NYSE:TEVA) on 9/9/2026 |
VTRS Viatris | $17.72 -2.2% | 9/9/2026 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Leerink Partners rating of Viatris (NASDAQ:VTRS) on 9/9/2026 |
SPRY ARS Pharmaceuticals | $4.31 -2.0% | 9/8/2026 | | Set Price Target | $15.00 | | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 9/8/2026 |
BLSM BlossomHill Therapeutics | $18.66 -12.7% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026 |
LTGO Latigo Biotherapeutics | $16.70 -7.7% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026 |
BLSM BlossomHill Therapeutics | $18.66 -12.7% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026 |
LTGO Latigo Biotherapeutics | $16.70 -7.7% | 9/1/2026 | | Initiated Coverage | $36.00 | Outperform | 00.00% | View details for Leerink Partners rating of Latigo Biotherapeutics (NASDAQ:LTGO) on 9/1/2026 |
ATTO Attovia Therapeutics | $17.14 -5.6% | 8/31/2026 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Attovia Therapeutics (NASDAQ:ATTO) on 8/31/2026 |
SCTX Scribe Therapeutics | $18.41 -20.1% | 8/18/2026 | | Initiated Coverage | $37.00 | Outperform | 00.00% | View details for Leerink Partners rating of Scribe Therapeutics (NASDAQ:SCTX) on 8/18/2026 |
REGN Regeneron Pharmaceuticals | $758.27 +1.0% | 8/17/2026 | | Boost Price Target | $641.00 ➝ $824.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Regeneron Pharmaceuticals (NASDAQ:REGN) on 8/17/2026 |
FRNM Freenome | $15.75 -1.1% | 8/14/2026 | | Initiated Coverage | $18.00 | Outperform | 00.00% | View details for Leerink Partners rating of Freenome (NASDAQ:FRNM) on 8/14/2026 |
LGND Ligand Pharmaceuticals | $312.37 +0.6% | 8/14/2026 | | Initiated Coverage | $330.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ligand Pharmaceuticals (NASDAQ:LGND) on 8/14/2026 |
SMMT Summit Therapeutics | $16.91 +3.2% | 8/12/2026 | | Upgrade | $12.00 ➝ $13.00 | Underperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Summit Therapeutics (NASDAQ:SMMT) on 8/12/2026 |
CAH Cardinal Health | $223.12 -0.4% | 8/11/2026 | | Set Price Target | $292.00 | | 00.00% | View details for Leerink Partners rating of Cardinal Health (NYSE:CAH) on 8/11/2026 |
TENX Tenax Therapeutics | $1.89 +2.7% | 8/11/2026 | | Set Price Target | $4.00 | | 00.00% | View details for Leerink Partners rating of Tenax Therapeutics (NASDAQ:TENX) on 8/11/2026 |
IPHA Innate Pharma | $1.63 +1.9% | 8/11/2026 | | Upgrade | $4.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Innate Pharma (NASDAQ:IPHA) on 8/11/2026 |
NTRA Natera | $413.31 -0.3% | 8/7/2026 | | Set Price Target | $330.00 | | 00.00% | View details for Leerink Partners rating of Natera (NASDAQ:NTRA) on 8/7/2026 |
AKBA Akebia Therapeutics | $0.92 +3.8% | 8/7/2026 | | Downgrade | $1.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Akebia Therapeutics (NASDAQ:AKBA) on 8/7/2026 |
HALO Halozyme Therapeutics | $110.40 -1.0% | 8/7/2026 | | Upgrade | $83.00 ➝ $110.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Halozyme Therapeutics (NASDAQ:HALO) on 8/7/2026 |
GDRX GoodRx | $3.29 +1.9% | 8/6/2026 | | Set Price Target | $5.00 | | 00.00% | View details for Leerink Partners rating of GoodRx (NASDAQ:GDRX) on 8/6/2026 |
EXEL Exelixis | $58.41 -0.4% | 8/6/2026 | | Downgrade | $52.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Exelixis (NASDAQ:EXEL) on 8/6/2026 |
PODD Insulet | $130.56 -1.7% | 8/6/2026 | | Downgrade | $247.00 ➝ $145.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Insulet (NASDAQ:PODD) on 8/6/2026 |
ABBV AbbVie | $262.43 -0.3% | 8/5/2026 | | Boost Price Target | $245.00 ➝ $279.00 | Outperform | 00.00% | View details for Leerink Partners rating of AbbVie (NYSE:ABBV) on 8/5/2026 |
REPL Replimune Group | $13.24 +1.8% | 8/4/2026 | | Upgrade | $11.00 ➝ $17.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Replimune Group (NASDAQ:REPL) on 8/4/2026 |
KROS Keros Therapeutics | $11.40 +1.9% | 8/4/2026 | | Lower Price Target | $30.00 ➝ $23.00 | Outperform | 00.00% | View details for Leerink Partners rating of Keros Therapeutics (NASDAQ:KROS) on 8/4/2026 |
LNTH Lantheus | $99.53 +0.0% | 8/3/2026 | | Set Price Target | $102.50 | | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026 |
INCY Incyte | $121.35 -1.5% | 8/3/2026 | | Boost Price Target | $131.00 ➝ $155.00 | Outperform | 00.00% | View details for Leerink Partners rating of Incyte (NASDAQ:INCY) on 8/3/2026 |
LNTH Lantheus | $99.53 +0.0% | 8/3/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Lantheus (NASDAQ:LNTH) on 8/3/2026 |
BSX Boston Scientific | $43.75 -0.3% | 7/30/2026 | | Set Price Target | $60.00 | | 00.00% | View details for Leerink Partners rating of Boston Scientific (NYSE:BSX) on 7/30/2026 |
HUM Humana | $382.71 -1.1% | 7/30/2026 | | Upgrade | $513.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Humana (NYSE:HUM) on 7/30/2026 |
GOSS Gossamer Bio | $11.85 +2.3% | 7/28/2026 | | Upgrade | $80.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Gossamer Bio (NASDAQ:GOSS) on 7/28/2026 |
EW Edwards Lifesciences | $86.41 -1.9% | 7/24/2026 | | Upgrade | $87.00 ➝ $101.00 | Market Perform ➝ Outperform | 00.00% | View details for Leerink Partners rating of Edwards Lifesciences (NYSE:EW) on 7/24/2026 |
MEDP Medpace | $624.18 +0.3% | 7/23/2026 | | Set Price Target | $620.00 | | 00.00% | View details for Leerink Partners rating of Medpace (NASDAQ:MEDP) on 7/23/2026 |
PGNY Progyny | $25.19 +1.6% | 7/22/2026 | | Set Price Target | $38.00 | | 00.00% | View details for Leerink Partners rating of Progyny (NASDAQ:PGNY) on 7/22/2026 |
GILD Gilead Sciences | $149.05 -1.5% | 7/21/2026 | | Downgrade | $146.00 ➝ $127.00 | Outperform ➝ Market Perform | 00.00% | View details for Leerink Partners rating of Gilead Sciences (NASDAQ:GILD) on 7/21/2026 |
STTK Shattuck Labs | $6.82 +4.3% | 7/20/2026 | | Initiated Coverage | $16.00 | Outperform | 00.00% | View details for Leerink Partners rating of Shattuck Labs (NASDAQ:STTK) on 7/20/2026 |
ELV Elevance Health | $389.79 -0.7% | 7/17/2026 | | Boost Price Target | $364.00 ➝ $395.00 | Market Perform | 00.00% | View details for Leerink Partners rating of Elevance Health (NYSE:ELV) on 7/17/2026 |
ILMN Illumina | $273.68 +0.6% | 7/17/2026 | | Boost Price Target | $175.00 ➝ $210.00 | Outperform | 00.00% | View details for Leerink Partners rating of Illumina (NASDAQ:ILMN) on 7/17/2026 |
TXG 10x Genomics | $90.36 +0.4% | 7/17/2026 | | Boost Price Target | $23.00 ➝ $40.00 | Market Perform | 00.00% | View details for Leerink Partners rating of 10x Genomics (NASDAQ:TXG) on 7/17/2026 |
ISRG Intuitive Surgical | $406.63 -1.3% | 7/17/2026 | | Lower Price Target | $573.00 ➝ $454.00 | Outperform | 00.00% | View details for Leerink Partners rating of Intuitive Surgical (NASDAQ:ISRG) on 7/17/2026 |
UNH UnitedHealth Group | $367.89 -1.9% | 7/17/2026 | | Boost Price Target | $462.00 ➝ $472.00 | Outperform | 00.00% | View details for Leerink Partners rating of UnitedHealth Group (NYSE:UNH) on 7/17/2026 |
TWST Twist Bioscience | $193.24 +3.8% | 7/16/2026 | | Set Price Target | $110.00 | | 00.00% | View details for Leerink Partners rating of Twist Bioscience (NASDAQ:TWST) on 7/16/2026 |
KARD Kardigan | $14.75 +0.6% | 7/13/2026 | | Initiated Coverage | $37.00 | Outperform | 00.00% | View details for Leerink Partners rating of Kardigan (NASDAQ:KARD) on 7/13/2026 |
NGEN NervGen Pharma | $1.91 -0.5% | 7/13/2026 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Leerink Partners rating of NervGen Pharma (NASDAQ:NGEN) on 7/13/2026 |
WHWK Whitehawk Therapeutics | $3.76 +0.8% | 7/13/2026 | | Initiated Coverage | $9.00 | Outperform | 00.00% | View details for Leerink Partners rating of Whitehawk Therapeutics (NASDAQ:WHWK) on 7/13/2026 |
BRKR Bruker | $64.75 +0.4% | 7/7/2026 | | Boost Price Target | $60.00 ➝ $70.00 | Outperform | 00.00% | View details for Leerink Partners rating of Bruker (NASDAQ:BRKR) on 7/7/2026 |
AVTX Avalo Therapeutics | $15.33 -1.6% | 7/6/2026 | | Initiated Coverage | $38.00 | Outperform | 00.00% | View details for Leerink Partners rating of Avalo Therapeutics (NASDAQ:AVTX) on 7/6/2026 |
PBLS Parabilis Medicines | $32.29 +1.2% | 7/6/2026 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Leerink Partners rating of Parabilis Medicines (NASDAQ:PBLS) on 7/6/2026 |
"How Much Can I Actually Spend Each Year With $2.5M Saved?" (Ad) Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it.
Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio.
A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors. Take the free quiz to get matched with a fiduciary advisor |
PYXS Pyxis Oncology | $2.33 -19.7% | 7/2/2026 | | Lower Price Target | $9.00 ➝ $7.00 | Outperform | 00.00% | View details for Leerink Partners rating of Pyxis Oncology (NASDAQ:PYXS) on 7/2/2026 |
MLTX MoonLake Immunotherapeutics | $11.70 +2.2% | 7/1/2026 | | Boost Price Target | $24.00 ➝ $29.00 | Outperform | 00.00% | View details for Leerink Partners rating of MoonLake Immunotherapeutics (NASDAQ:MLTX) on 7/1/2026 |
ABVX Abivax | $99.02 +0.5% | 6/30/2026 | | Boost Price Target | $140.00 ➝ $148.00 | Outperform | 00.00% | View details for Leerink Partners rating of Abivax (NASDAQ:ABVX) on 6/30/2026 |
TECH Bio-Techne | $72.47 +0.1% | 6/25/2026 | | Set Price Target | $73.00 | | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
LLY Eli Lilly and Company | $1,161.73 -1.9% | 6/25/2026 | | Boost Price Target | $1,119.00 ➝ $1,232.00 | Outperform | 00.00% | View details for Leerink Partners rating of Eli Lilly and Company (NYSE:LLY) on 6/25/2026 |
IONS Ionis Pharmaceuticals | $44.65 -2.7% | 6/25/2026 | | Boost Price Target | $122.00 ➝ $129.00 | Outperform | 00.00% | View details for Leerink Partners rating of Ionis Pharmaceuticals (NASDAQ:IONS) on 6/25/2026 |
SPRY ARS Pharmaceuticals | $4.31 -2.0% | 6/25/2026 | | Lower Price Target | $25.00 ➝ $24.00 | Outperform | 00.00% | View details for Leerink Partners rating of ARS Pharmaceuticals (NASDAQ:SPRY) on 6/25/2026 |
TECH Bio-Techne | $72.47 +0.1% | 6/25/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Leerink Partners rating of Bio-Techne (NASDAQ:TECH) on 6/25/2026 |
QNCX Quince Therapeutics | $31.01 -0.5% | 6/24/2026 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for Leerink Partners rating of Quince Therapeutics (NASDAQ:QNCX) on 6/24/2026 |
RAPP Rapport Therapeutics | $33.60 +1.8% | 6/24/2026 | | Initiated Coverage | $52.00 | Outperform | 00.00% | View details for Leerink Partners rating of Rapport Therapeutics (NASDAQ:RAPP) on 6/24/2026 |